Health and Healthcare

MannKind : MNKD

All MannKind Articles

305 Articles

Chris Lange | Jan 8, 2015 at 10:25 AM EST

6 Serious Biotech and Health Care Movers

In Thursday morning’s trading session, it seemed almost across the board that biotech stocks were the largest gainers.

Trey Thoelcke | Dec 26, 2014 at 6:45 AM EST

The 5 Most Shorted Nasdaq Stocks in Mid-December

Among the most heavily shorted stocks traded on the Nasdaq between the November 28 and December 15 settlement dates, only…

Chris Lange | Dec 10, 2014 at 10:00 AM EST

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top…

Trey Thoelcke | Dec 10, 2014 at 6:53 AM EST

The 5 Most Shorted Stocks on the Nasdaq

Among the most heavily shorted Nasdaq stocks between the November 14 and November 28 settlement dates, only BlackBerry saw a…

Jon C. Ogg | Dec 4, 2014 at 12:10 PM EST

MannKind Sees More Insider Selling

MannKind saw its shares trading lower on Thursday. The culprit may simply be insiders selling more shares.

Chris Lange | Nov 26, 2014 at 11:07 AM EST

Mixed Readings For Biotech Short Interest

ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | Nov 12, 2014 at 8:40 AM EST

Biotech Short Interest Becomes Stock Specific (Updated)

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.

Trey Thoelcke | Nov 12, 2014 at 7:00 AM EST

The 5 Most-Heavily Shorted Nasdaq Stocks

Surges in short interest in Intel and Comcast between the October 15 and October 31 settlement dates made sure they…

Jon C. Ogg | Nov 3, 2014 at 2:00 PM EST

MannKind Spending Trends See Improvements

MannKind reported its third-quarter financial results on Monday morning.

Chris Lange | Oct 27, 2014 at 10:30 AM EDT

Biotech Short Interest Becomes Stock Specific

Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.

Jon C. Ogg | Oct 20, 2014 at 1:30 PM EDT

Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade

Goldman Sachs has initiated on MannKind with a Neutral rating and a $6 price target, a move that may seem…

Jon C. Ogg | Oct 20, 2014 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: AIG, Align Tech, Cliffs, Cyber-Ark, MannKind, Micron and More

These are the top analyst upgrades and downgrades featured by 24/7 Wall St. for Monday, October 20, 2014.

Chris Lange | Oct 10, 2014 at 10:10 AM EDT

Short Interest in Biotech Becomes Company Specific

The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the…

Trey Thoelcke | Oct 10, 2014 at 6:47 AM EDT

Apple Slips From 5 Most Shorted Nasdaq Stocks

While Apple was slipping down the list of the most shorted stocks on the Nasdaq, it passed Microsoft on the…

Jon C. Ogg | Sep 25, 2014 at 10:50 AM EDT

Short Sellers Make Moves in Key Biotech Stocks

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most…

1 … 14 15 16 17 18 … 21

MannKind : MNKD

All MannKind Articles

6 Serious Biotech and Health Care Movers

The 5 Most Shorted Nasdaq Stocks in Mid-December

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The 5 Most Shorted Stocks on the Nasdaq

MannKind Sees More Insider Selling

Mixed Readings For Biotech Short Interest

Biotech Short Interest Becomes Stock Specific (Updated)

The 5 Most-Heavily Shorted Nasdaq Stocks

MannKind Spending Trends See Improvements

Biotech Short Interest Becomes Stock Specific

Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade

Top Analyst Upgrades and Downgrades: AIG, Align Tech, Cliffs, Cyber-Ark, MannKind, Micron and More

Short Interest in Biotech Becomes Company Specific

Apple Slips From 5 Most Shorted Nasdaq Stocks

Short Sellers Make Moves in Key Biotech Stocks

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

MannKind : MNKD

All MannKind Articles

6 Serious Biotech and Health Care Movers

The 5 Most Shorted Nasdaq Stocks in Mid-December

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The 5 Most Shorted Stocks on the Nasdaq

MannKind Sees More Insider Selling

Mixed Readings For Biotech Short Interest

Biotech Short Interest Becomes Stock Specific (Updated)

The 5 Most-Heavily Shorted Nasdaq Stocks

MannKind Spending Trends See Improvements

Biotech Short Interest Becomes Stock Specific

Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade

Top Analyst Upgrades and Downgrades: AIG, Align Tech, Cliffs, Cyber-Ark, MannKind, Micron and More

Short Interest in Biotech Becomes Company Specific

Apple Slips From 5 Most Shorted Nasdaq Stocks

Short Sellers Make Moves in Key Biotech Stocks

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do